<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>     caa a22        4500</leader>
  <controlfield tag="001">469053461</controlfield>
  <controlfield tag="003">CHVBK</controlfield>
  <controlfield tag="005">20180323132836.0</controlfield>
  <controlfield tag="007">cr unu---uuuuu</controlfield>
  <controlfield tag="008">170328e19920601xx      s     000 0 eng  </controlfield>
  <datafield tag="024" ind1="7" ind2="0">
   <subfield code="a">10.1007/BF00123380</subfield>
   <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(NATIONALLICENCE)springer-10.1007/BF00123380</subfield>
  </datafield>
  <datafield tag="245" ind1="0" ind2="0">
   <subfield code="a">PLS modelling of structure—activity relationships of catechol O -methyltransferase inhibitors</subfield>
   <subfield code="h">[Elektronische Daten]</subfield>
   <subfield code="c">[Timo Lotta, Jyrki Taskinen, Reijo Bäckström, Erkki Nissinen]</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
   <subfield code="a">Summary: Quantitative structure-activity analysis was carried out for in vitro inhibition of rat brain soluble catechol O-methyltransferase by a series (N=99) of 1,5-substituted-3,4-dihydroxybenzenes using computational chemistry and multivariate PLS modelling of data sets. The molecular structural descriptors (N=19) associated with the electronics of the catecholic ring and sizes of substituents were derived theoretically. For the whole set of molecules two separate PLS models have to be used. A PLS model with two significant (crossvalidated) model dimensions describing 82.2% of the variance in inhibition activity data was capable of predicting all molecules except those having the largest R1 substituent or having a large R5 substituent compared to the NO2 group. The other PLS model with three significant (crossvalidated) model dimensions described 83.3% of the variance in inhibition activity data. This model could not handle compounds having a small R5 substituent, compared to the NO2 group, or the largest R1 substituent. The predictive capability of these PLS models was good. The models reveal that inhibition activity is nonlinearly related to the size of the R5 substituent. The analysis of the PLS models also shows that the binding affinity is greatly dependent on the electronic nature of both R1 and R5 substituents. The electron-withdrawing nature of the substituents enhances inhibition activity. In addition, the size of the R1 substituent and its lipophilicity are important in the binding of inhibitors. The size of the R1 substituent has an upper limit. On the other hand, ionized R1 substituents decrease inhibition activity.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
   <subfield code="a">ESCOM Science Publishers B.V, 1992</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">QSAR</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Computational chemistry</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">PLS</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Multivariate</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">COMT</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Catechols</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Lotta</subfield>
   <subfield code="D">Timo</subfield>
   <subfield code="u">Orion Research Center, Orion Corporation, Orion-Farmos Pharmaceuticals, P.O. Box 65, SF-02101, Espoo, Finland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Taskinen</subfield>
   <subfield code="D">Jyrki</subfield>
   <subfield code="u">Orion Research Center, Orion Corporation, Orion-Farmos Pharmaceuticals, P.O. Box 65, SF-02101, Espoo, Finland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Bäckström</subfield>
   <subfield code="D">Reijo</subfield>
   <subfield code="u">Orion Research Center, Orion Corporation, Orion-Farmos Pharmaceuticals, P.O. Box 65, SF-02101, Espoo, Finland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Nissinen</subfield>
   <subfield code="D">Erkki</subfield>
   <subfield code="u">Orion Research Center, Orion Corporation, Orion-Farmos Pharmaceuticals, P.O. Box 65, SF-02101, Espoo, Finland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
   <subfield code="t">Journal of Computer-Aided Molecular Design</subfield>
   <subfield code="d">Kluwer Academic Publishers</subfield>
   <subfield code="g">6/3(1992-06-01), 253-272</subfield>
   <subfield code="x">0920-654X</subfield>
   <subfield code="q">6:3&lt;253</subfield>
   <subfield code="1">1992</subfield>
   <subfield code="2">6</subfield>
   <subfield code="o">10822</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
   <subfield code="u">https://doi.org/10.1007/BF00123380</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="908" ind1=" " ind2=" ">
   <subfield code="D">1</subfield>
   <subfield code="a">research-article</subfield>
   <subfield code="2">jats</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">856</subfield>
   <subfield code="E">40</subfield>
   <subfield code="u">https://doi.org/10.1007/BF00123380</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Lotta</subfield>
   <subfield code="D">Timo</subfield>
   <subfield code="u">Orion Research Center, Orion Corporation, Orion-Farmos Pharmaceuticals, P.O. Box 65, SF-02101, Espoo, Finland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Taskinen</subfield>
   <subfield code="D">Jyrki</subfield>
   <subfield code="u">Orion Research Center, Orion Corporation, Orion-Farmos Pharmaceuticals, P.O. Box 65, SF-02101, Espoo, Finland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Bäckström</subfield>
   <subfield code="D">Reijo</subfield>
   <subfield code="u">Orion Research Center, Orion Corporation, Orion-Farmos Pharmaceuticals, P.O. Box 65, SF-02101, Espoo, Finland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Nissinen</subfield>
   <subfield code="D">Erkki</subfield>
   <subfield code="u">Orion Research Center, Orion Corporation, Orion-Farmos Pharmaceuticals, P.O. Box 65, SF-02101, Espoo, Finland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">773</subfield>
   <subfield code="E">0-</subfield>
   <subfield code="t">Journal of Computer-Aided Molecular Design</subfield>
   <subfield code="d">Kluwer Academic Publishers</subfield>
   <subfield code="g">6/3(1992-06-01), 253-272</subfield>
   <subfield code="x">0920-654X</subfield>
   <subfield code="q">6:3&lt;253</subfield>
   <subfield code="1">1992</subfield>
   <subfield code="2">6</subfield>
   <subfield code="o">10822</subfield>
  </datafield>
  <datafield tag="900" ind1=" " ind2="7">
   <subfield code="a">Metadata rights reserved</subfield>
   <subfield code="b">Springer special CC-BY-NC licence</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="898" ind1=" " ind2=" ">
   <subfield code="a">BK010053</subfield>
   <subfield code="b">XK010053</subfield>
   <subfield code="c">XK010000</subfield>
  </datafield>
  <datafield tag="949" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="F">NATIONALLICENCE</subfield>
   <subfield code="b">NL-springer</subfield>
  </datafield>
 </record>
</collection>
